Scholars@Duke
Daniel Bryce Landi

Daniel Bryce Landi

Assistant Professor of Pediatrics
Pediatrics, Hematology-Oncology
daniel.landi@duke.edu
Box 102382, Durham, NC 27710
330 Trent Drive, Room 390, Durham, NC 27710

Selected Publications

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Journal Article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Link to item Cite

The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.

Journal Article J Neurosurg Pediatr · April 1, 2024 OBJECTIVE: Relatively little is known about the safety and accuracy of catheter placement for oncolytic viral therapy in children with malignant brain tumors. Accordingly, this study combines data from two phase I clinical trials that employed viral immuno ... Full text Link to item Cite

Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes.

Journal Article Cancer Epidemiol Biomarkers Prev · March 1, 2024 BACKGROUND: The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs. METHODS: We surveyed parents of children with cancer regarding maternal gestat ... Full text Link to item Cite

Supplementary Table S1 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Comparison of demographic characteristics of respondents reporting any maternal substance use during pregnancy vs. those reporting no substance use</p> ... Full text Cite

Supplementary Table S1 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Comparison of demographic characteristics of respondents reporting any maternal substance use during pregnancy vs. those reporting no substance use</p> ... Full text Cite

Supplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents</p> ... Full text Cite

Data from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <div>AbstractBackground:<p>The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.</p>Methods:<p>We surveyed paren ... Full text Cite

Supplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Univariate associations between prenatal substance use and childhood cancer subtype</p> ... Full text Cite

Supplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Univariate associations between prenatal substance use and childhood cancer subtype</p> ... Full text Cite

Supplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <p>Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents</p> ... Full text Cite

Data from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes

Other · March 1, 2024 <div>AbstractBackground:<p>The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.</p>Methods:<p>We surveyed paren ... Full text Cite

Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019.

Journal Article Neurooncol Pract · February 2024 BACKGROUND: The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-bas ... Full text Link to item Cite

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Journal Article Nat Med · January 2024 BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system-penetrant, type II ... Full text Link to item Cite

A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.

Journal Article Clin Cancer Res · December 15, 2023 PURPOSE: Treatment of wingless (WNT)-activated medulloblastoma (WNT+MB) with surgery, irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy of therapy de-intensification by omitting XRT entirely in children with WNT+MB. ... Full text Link to item Cite

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Journal Article Lancet Child Adolesc Health · July 2023 BACKGROUND: Outcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric ... Full text Link to item Cite

Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors.

Journal Article J Pediatr Hematol Oncol · May 1, 2023 Low-grade gliomas/glioneuronal tumors comprise one-third of all pediatric-type CNS tumors. These tumors are generally caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Targeted drugs, such as trametinib, have shown prom ... Full text Link to item Cite

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils.

Journal Article J Immunother Cancer · April 2023 BACKGROUND: Antitumor mechanisms of CD4+ T cells remain crudely defined, and means to effectively harness CD4+ T-cell help for cancer immunotherapy are lacking. Pre-existing memory CD4+ T cells hold potential to be leveraged for this purpose. Moreover, the ... Full text Link to item Cite

Assisted reproductive technology and association with childhood cancer subtypes.

Journal Article Cancer Med · February 2023 OBJECTIVES: To investigate the association between assisted reproductive technology (ART) use and childhood cancer subtype. STUDY DESIGN: We deployed a cross-sectional survey of 1701 parents of children with cancer about their ART use, demographics, and ge ... Full text Link to item Cite

Incidence and survival of choroid plexus tumors in the United States.

Journal Article Neurooncol Pract · February 2023 BACKGROUND: There are limited data available on incidence and survival of patients with choroid plexus tumors (CPT). This study provides the most current epidemiological analysis of choroid plexus tumors from 2004 to 2017 in the United States. METHODS: Dat ... Full text Link to item Cite

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · December 2022 Central nervous system (CNS) cancers account for approximately one quarter of all pediatric tumors and are the leading cause of cancer-related death in children. More than 4,000 brain and CNS tumors are diagnosed each year in children and teens, and the in ... Full text Link to item Cite

Epidemiology of pineoblastoma in the United States, 2000-2017.

Journal Article Neurooncol Pract · April 2022 BACKGROUND: Pineoblastoma (PB) is a rare malignant brain tumor originating in the pineal gland. Here, we provide a comprehensive epidemiological analysis of PB in the United States from 2000 to 2017. METHODS: Data on 1133 patients with PB were acquired fro ... Full text Link to item Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ... Full text Open Access Link to item Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference Neuro-Oncology · November 12, 2021 AbstractIsocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for t ... Full text Open Access Link to item Cite

QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS

Conference Neuro-Oncology · November 12, 2021 AbstractGlioblastoma (GBM) patients can use tumor-treating fields (TTFs) with adjuvant temozolomide (TMZ) to treat their disease. TTFs involve wearing transfixed transducers to the shaved scalp, and the tran ... Full text Open Access Link to item Cite

INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThe use of telemedicine increased during the COVID-19 pandemic. However, the impact on patient satisfaction in the ... Full text Open Access Cite

CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONVaccination with dendritic cells (DCs) fares poorly in primary and recurrent glioblastoma (GBM). Moreover, GBM vac ... Full text Open Access Link to item Cite

IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDRecurrent glioblastoma (rGBM) is rapidly fatal (median overall survival [mOS] of ~9 months; OS at 12 months [OS12] & ... Full text Cite

EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractGlioblastoma (GBM) is the most aggressive primary brain cancer with a median survival of less than 16 months. This dire prognosis signifies the urgent need for improved treatment options, such as imm ... Full text Cite

CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDRecurrent glioblastoma (rGBM) is rapidly fatal with current therapies. PVSRIPO is an intratumoral immunotherapy targ ... Full text Cite

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · June 1, 2021 AbstractIntroductionThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Link to item Cite

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS

Conference Neuro-Oncology · June 1, 2021 AbstractCircumscribed low-grade gliomas comprise roughly one-third of pediatric CNS tumors. Most of these tumors are caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Dru ... Full text Cite

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2065 Background: The prognosis for patients (pts) with recurrent (r) glioblastoma (GBM) is poor, with no highly effective approved therapies. Treatment failure may result from poor penetration of drugs through the blood-brain ... Full text Cite

FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS10056 Background: The mitogen-activated protein kinase (MAPK) signaling pathway is an essential pathway that regulates key cell functions such as growth, survival, and differentiation. Genomic alterations and dysregulation of ... Full text Cite

THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDH3 K27M-mutant diffuse midline glioma (DMG) is invariably lethal. Viruses naturally engage innate immunity, induce a ... Full text Cite

EPID-16. INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDPediatric neuro-oncology (PNO) survivors suffer long-term physical and neurocognitive morbidity. Comprehensive care ... Full text Cite

MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDWnt+ medulloblastoma (WPM) is a favorable subtype with EFS &gt; 90% when treating postoperatively with craniospi ... Full text Cite

EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDRecurrent medulloblastoma and malignant glioma are lethal tumors that are virtually incurable. The cytomegalovirus ( ... Full text Cite

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Open Access Link to item Cite

BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONBRAF is a RAF-family kinase that regulates MAPK/ERK signaling. Activating BRAF mutations, including V600E, are com ... Full text Cite

CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG)

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDD2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR-wt and mutant-specific (EGF ... Full text Cite

DDRE-20. GENERATION OF A HIGH-AFFINITY EGFR/EGFRvIII-TARGETED D2C7 CAR-T CELL

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDThe intent of this investigation is to validate a novel, high-affinity epidermal growth factor receptor (EGFR) chime ... Full text Cite

QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDPrimary brain tumor patients experience high levels of distress due to their diagnosis and treatment leading to chan ... Full text Cite

Current medulloblastoma subgroup specific clinical trials.

Journal Article Transl Pediatr · April 2020 Medulloblastoma is a heterogeneous disease with at least four distinct molecular subgroups: wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4. Recently there has been considerable progress defining the molecular drivers and prognostic factors of e ... Full text Link to item Cite

QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY

Conference Neuro-Oncology · November 11, 2019 AbstractWith a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress of the patient are important in the clinical care of the patient. Mindfulness meditation is a mi ... Full text Link to item Cite

PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS

Conference Neuro-Oncology · November 11, 2019 AbstractBACKGROUNDRecurrent medulloblastoma and malignant glioma are virtually incurable. In children, these tumors are often dissemin ... Full text Cite

QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS

Conference Neuro-Oncology · November 11, 2019 AbstractCircumscribed low-grade glioma is generally driven by MAP kinase pathway activation, and this discovery motivates use of the non-competitive MEK 1/2 inhibitor trametinib for children and adults with ... Full text Cite

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Journal Article J Neurooncol · November 2018 INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare Grade II and III glioma. Surgical resection is the mainstay of treatment, however, adjuvant therapy is sometimes necessary. Given the rarity of PXA, chemotherapeutic efficacy data is limited. The ... Full text Link to item Cite

Novel case of recurrent intraventricular atypical central neurocytoma with prominent gangliogliomatous differentiation in a 10-year-old boy with 10 years of follow up.

Journal Article Neuropathology · October 2018 Central neurocytoma is a rare neuronal tumor that typically occurs in young adults. Infrequently, these tumors exhibit advanced neuronal maturation and glial differentiation, giving rise to a histologically diverse tumor, in contrast to a typical central n ... Full text Link to item Cite

Immunotherapy for pediatric brain tumors

Journal Article Neuroimmunology and Neuroinflammation · July 23, 2018 Full text Cite

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Journal Article Cancer Res · January 15, 2018 Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell-based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was disco ... Full text Link to item Cite

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Journal Article JAMA Oncol · August 1, 2017 IMPORTANCE: Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. OBJECTIVE: To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)-modified virus-specific T cells (VSTs) is saf ... Full text Link to item Cite

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Journal Article J Clin Invest · August 1, 2016 In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that are redirected to single tumor antigens. Given the heterogeneous expression of antigens on glioblastomas, we hypothesized that ... Full text Link to item Cite

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.

Journal Article J Neurooncol · November 2015 While the 5-year overall survival is better in pediatric than in adult patients diagnosed with glioblastoma (GBM), outcomes in children remain very poor. Understanding the mechanisms of tumorigenesis and tumor propagation can identify therapeutic targets t ... Full text Link to item Cite

Differences in pain management between hematologists and hospitalists caring for patients with sickle cell disease hospitalized for vasoocclusive crisis.

Journal Article Clin J Pain · March 2014 OBJECTIVES: Sickle cell disease (SCD) is a chronic disease characterized by multiple vaso-occlusive complications and is increasingly cared for by hospitalists. The purpose of this study is to examine differences in pain management between hematologists an ... Full text Link to item Cite

Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy.

Journal Article Front Oncol · 2014 Malignant gliomas are the most common primary brain tumor in adults, with over 12,000 new cases diagnosed in the United States each year. Over the last decade, investigators have reliably identified human cytomegalovirus (HCMV) proteins, nucleic acids, and ... Full text Link to item Cite

Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

Journal Article Blood · May 9, 2013 We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil r ... Full text Open Access Link to item Cite

Characteristics of abdominal vein thrombosis in children and adults.

Journal Article Thromb Haemost · April 2013 The demographic and clinical characteristics of adults and children with lower extremity deep-vein thrombosis and/or pulmonary embolism (LE DVT/PE) may differ from those with abdominal vein thrombosis (abdominal VT). Abdominal VT can be a presenting sign o ... Full text Open Access Link to item Cite

Report of a young girl with MYH9 mutation and review of the literature.

Journal Article J Pediatr Hematol Oncol · October 2012 Featured Publication MYH9 mutations cause the inherited macro-thrombocytopenic syndromes of May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome, and Epstein syndrome, collectively referred to as MYH9-related disease. We present the case of a girl with MYH9-related disea ... Full text Open Access Link to item Cite

Complications of implantable venous access devices in patients with sickle cell disease.

Journal Article Am J Hematol · February 2012 Featured Publication Implantable venous access devices (VADs) are used in sickle cell disease (SCD) for patients with poor venous access to facilitate chronic blood transfusions and manage acute complications. We attempted to define the frequency of bloodstream infections (BSI ... Full text Open Access Link to item Cite

Presentation and outcomes for children with bone marrow necrosis and acute lymphoblastic leukemia: a literature review.

Journal Article J Pediatr Hematol Oncol · October 2011 Bone marrow necrosis is a rare histopathology finding with the majority of cases occurring in the setting of a hematologic malignancy. This article reports a case of diffuse marrow necrosis in a child secondary to acute lymphoblastic leukemia and summarize ... Full text Open Access Link to item Cite

MEASURING ANTIBODY-SECRETING B-CELL RESPONSES TO IMMUNOLOGICAL STIMULI.

Conference Journal of Investigative Medicine · January 2007 Full text Cite

A Sheep in Wolf’s Clothing: An Atypical Etiology of a Cerebellar Lesion.

Conference nitial History/Presentation: A 12-year-old, previously healthy female presented with acute, intractable headaches. Headaches were preceded by one month of lethargy, myalgias, upper respiratory symptoms, and 8-pound weight loss. Symptoms rapidly progressed ... Cite

A Sheep in Wolf’s Clothing: An Atypical Etiology of a Cerebellar Lesion.

Conference nitial History/Presentation: A 12-year-old, previously healthy female presented with acute, intractable headaches. Headaches were preceded by one month of lethargy, myalgias, upper respiratory symptoms, and 8-pound weight loss. Symptoms rapidly progressed ... Cite

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Conference Journal of Clinical Oncology FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. ... Full text Link to item Cite